FDA Expands Marstacimab Indication in Hemophilia A and B - Top-Institutions - MDSpire

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.

  • By

  • Kathryn Wighton

  • June 8, 2026

  • 3 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    McMaster University/Hamilton Health Sciences
    McMaster University/Hamilton Health Sciences

    Hamilton, Ontario

    Key Differentiators

    • Hematology
    • Thrombosis

  • #2

    Northwell Health Hemostasis & Thrombosis Center
    Northwell Health Hemostasis & Thrombosis Center

    New Hyde Park, New York

    Key Differentiators

    • Hematology
    • Thrombosis

Original Source(s)

FDA Expands Marstacimab Indication in Hemophilia A and B

  • by Kathryn Wighton

  • June 8, 2026

Related Content

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Breastfeeding May Help Infants Achieve Adequate Sleep

A nationwide birth cohort found lower odds of short sleep at 1 year among infants breastfed during the first 6 months of life, regardless of formula supplementation.

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.